HR 7050119th CongressIn Committee
Homeopathic Drug Product Safety, Quality, and Transparency Act
Standard Summary
Balanced plain-English summary
This bill creates a distinct federal regulatory pathway for homeopathic drug products by amending the Food, Drug, and Cosmetic Act to establish safety, quality, labeling, manufacturing, registration, and advisory committee requirements while prohibiting premarket approval and withdrawing prior FDA guidance.
Key Points
- 1Defines homeopathic drug products and homeopathic ingredients under federal law
- 2Sets adulteration and good manufacturing practice standards tied to the Homeopathic Pharmacopoeia or consensus standards
- 3Establishes labeling requirements, including a disclaimer and source information for indications
- 4Bars premarket approval and creates a Homeopathic Drug Product Advisory Committee
- 5Withdraws the 2022 FDA homeopathic drug guidance and limits certain FTC and state substantiation claims
Impact Areas
Homeopathic drug manufacturersConsumers and homeopathic practitionersFood and Drug AdministrationFederal Trade CommissionState regulators
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026